Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q1 2023 financial results and corporate highlights. The company, focused on developing engineered natural killer (NK) cell therapies, announced:
1. Clinical updates for NKX101 expected in Q2 2023 and NKX019 in H2 2023.
2. Cash and cash equivalents of $332.1 million as of March 31, 2023.
3. Cash runway anticipated to fund operations into 2025.
4. Net loss of $30.8 million, or $0.63 per share, for Q1 2023.
5. R&D expenses of $26.1 million and G&A expenses of $8.2 million for Q1 2023.
The company plans to present additional clinical data for both NKX101 and NKX019 in their respective ongoing Phase 1 trials. Nkarta also announced the resignation of its CFO and business officer, Nadir Mahmood, PhD, effective June 30, 2023.
Summary not available.
Nkarta, Inc. (Nasdaq: NKTX) presented groundbreaking preclinical data at the 2023 AACR Annual Meeting, highlighting the enhanced efficacy of engineered natural killer (NK) cell therapies. The studies showcased the combination of NKX101, targeting the NKG2D receptor, with the monoclonal antibody cetuximab, leading to significant improvements in cancer cell killing in vitro. Additionally, researchers demonstrated that ADAM17 gene knockout in NK or CAR NK cells enhances antibody-dependent cellular cytotoxicity (ADCC) and overall anti-tumor activity. These findings emphasize the potential of NKX101 and ADAM17 KO therapies in treating solid tumors, marking a critical step toward clinical application. The studies support further exploration of NK cell therapies combined with therapeutic antibodies for improved anti-tumor treatments.
Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in two investor conferences:
- 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:00 p.m. ET - featuring a fireside chat.
- Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET - featuring a panel discussion.
Webcasts of these events will be available on the Investors section of Nkarta's website, with replays archived for approximately 90 days. Nkarta specializes in off-the-shelf NK cell therapies aimed at providing broad access and deep anti-tumor activity in outpatient settings, utilizing advanced cell engineering technologies.
Nkarta, Inc. (NASDAQ: NKTX) announced that its CFO, Nadir Mahmood, PhD, has resigned to become CEO of another biotech firm, remaining until June 30, 2023, to ensure a smooth transition. Nkarta is on schedule to release updated results from its NKX101 clinical trial in Q2 2023 and is initiating external searches for a new CFO. This transition follows Mahmood's five years at Nkarta, highlighted by his contributions to advancing NK cell therapies aimed at treating cancer. Nkarta remains focused on developing its pipeline and maintaining progress in clinical trials.